We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Axis-Shield | LSE:ASD | London | Ordinary Share | GB0008039975 | ORD 35P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 469.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:2382B Axis-Shield PLC 10 April 2006 AFINION(TM) POINT-OF-CARE SYSTEM FROM AXIS-SHIELD PLC IS SELECTED AS A WINNER IN THE 2006 MEDICAL DESIGN EXCELLENCE AWARDS COMPETITION Dundee, Scotland, 10 April 2006: Axis-Shield (LSE:ASD, OSE:ASD), the international in vitro diagnostics company, today announces that its novel AFINION(TM) Point-of-Care System has been selected as a winner in the US-based Medical Design Excellence Awards (MDEA) competition, the prestigious awards programme for the medical technology community. The awards recognize the many people including engineers, scientists, designers, and clinicians, who are responsible for the groundbreaking innovations that are changing the face of healthcare. MDEA-winning entries excel in the areas of product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery. Whether the product can change traditional medical attitudes or practices and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives, are particularly relevant in the judging process. A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics. Svein Lien, Axis-Shield CEO, commented: "We are very pleased that our AFINION(TM) System has been recognised in this way and that our significant investment in this ground-breaking platform to improve diagnosis at the point of care has achieved this US accolade. It complements the earlier European acknowledgement we achieved through our award for innovation from Den Norske Bank in Norway. We believe customers and patients will appreciate the elegance and accuracy of AFINION(TM) and its ability to deliver quick test results using a very simple procedure, when we launch the product in the USA later this year." Enquiries: Axis-Shield plc Svein Lien, CEO Tel: +47 22 700616 Paul Garvey, Finance Director Tel: +44 1382 422000 Financial Dynamics David Yates / Sarah Macleod Tel: +44 207 831 3113 Notes to Editors About Axis-Shield Axis-Shield is a global manufacturer of in vitro diagnostic kits with a focus on new markers in cardiovascular, rheumatoid, infectious and alcohol-related diseases, diabetes, dementia and near patient testing to facilitate improved patient management. News releases and company information are available at www.axis-shield.com About MDEA Visit www.MDEAwards.com This information is provided by RNS The company news service from the London Stock Exchange END MSCEAKLXEANKEFE
1 Year Axis-shield Chart |
1 Month Axis-shield Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions